Lara S. Sullivan's Insider Trades & SAST Disclosures
Lara S. Sullivan's most recent trade in Pyxis Oncology Inc was a trade of 918,308 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lara S. Sullivan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President ,CEO & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 918,308 | 918,308 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 1,135,000 | 1,135,000 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | S. Lara Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 1,071,242 | 1,071,242 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 990,461 | 990,461 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 990,461 | 0 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 703,379 | 2,155,699 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 61,825 | 61,825 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Mar 2023 | 61,825 | 0 | - | - | Stock Option (Right to buy) | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 95,684 | 1,452,320 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 742,574 | 1,041,363 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Lara S. Sullivan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 962,289 | 962,289 | - | - | Stock Option (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges